Biotechnology · South San Francisco, California, United States
$2.59
-1.15% (-$0.03)2026-08-24
Smart-Money SignalNeutral · 48/100— Insiders are net sellers over 90 days (-$5K, 1 sale vs 1 buy)
Revenue$0
Net Income-$40.4M
EPS$-0.92
Market Cap$185.5M
Price Performance
Historical data including institutional events
Company Profile
P
Paul Hastings
CEO & Executive Director
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
